In leukemia, such as MDS/AML, chromatin dysregulation plays a critical role through mutations in key DNA and histone modifiers, for example TET2, DNMT3A, ASXL1, and EZH2, which as mentioned above are frequently mutated in MDS/AML (Table 1). This evidence concerns the gene TET2 and myelodysplastic syndrome.